默沙东-话题@MedSci

#默沙东#

121篇内容 | 4313人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1259957, encodeId=ee41125995e88, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=阿斯利康/默沙东的PARP抑制剂Lynparza获得欧盟批准，治疗转移性乳腺癌, objectType=article, longId=164061, objectId=5ae5164061d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ae5164061d3, replyNumber=0, likeNumber=99, createdTime=2019-04-12, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ae5164061d3, moduleTitle=阿斯利康/默沙东的PARP抑制剂Lynparza获得欧盟批准，治疗转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ae5164061d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259956, encodeId=bd63125995643, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=欧盟批准默沙东Keytruda的新剂量计划：每3周200mg改为每6周400mg, objectType=article, longId=163716, objectId=5a51163e1635, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a51163e1635, replyNumber=0, likeNumber=69, createdTime=2019-04-07, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a51163e1635, moduleTitle=欧盟批准默沙东Keytruda的新剂量计划：每3周200mg改为每6周400mg, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a51163e1635)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259955, encodeId=9e18125995513, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东3亿收购IMDZ, objectType=article, longId=160855, objectId=f5a71608550a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5a71608550a, replyNumber=0, likeNumber=52, createdTime=2019-02-24, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5a71608550a, moduleTitle=默沙东3亿收购IMDZ, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5a71608550a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259954, encodeId=a523125995473, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=103, createdTime=2019-02-20, rootId=0, userName=仁医06, userId=55683, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259953, encodeId=4e76125995350, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=卫材中国和默沙东中国共同举办仑伐替尼中国上市会, objectType=article, longId=158213, objectId=18091582130e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18091582130e, replyNumber=0, likeNumber=77, createdTime=2019-01-18, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18091582130e, moduleTitle=卫材中国和默沙东中国共同举办仑伐替尼中国上市会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18091582130e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259952, encodeId=9759125995211, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=罗氏、吉利德、默沙东……跨国公司高管大变动, objectType=article, longId=155664, objectId=902915566442, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=902915566442, replyNumber=0, likeNumber=0, createdTime=2018-12-14, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=902915566442, moduleTitle=罗氏、吉利德、默沙东……跨国公司高管大变动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=902915566442)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259951, encodeId=1aae1259951fa, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东达成6.95亿美元合作，豪赌NK细胞疗法, objectType=article, longId=150498, objectId=367b150498a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367b150498a4, replyNumber=0, likeNumber=63, createdTime=2018-10-08, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367b150498a4, moduleTitle=默沙东达成6.95亿美元合作，豪赌NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=367b150498a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259950, encodeId=aeb71259950dc, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东HIV新药Delstrigo和Pifeltro获得FDA批准上市, objectType=article, longId=147983, objectId=fcca14e983e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcca14e983e4, replyNumber=0, likeNumber=89, createdTime=2018-09-02, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcca14e983e4, moduleTitle=默沙东HIV新药Delstrigo和Pifeltro获得FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcca14e983e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259949, encodeId=b72a12599497a, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=重磅！默沙东Keytruda获批，第2个PD-1药物正式登陆中国, objectType=article, longId=145225, objectId=fba614522579, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fba614522579, replyNumber=0, likeNumber=74, createdTime=2018-07-28, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fba614522579, moduleTitle=重磅！默沙东Keytruda获批，第2个PD-1药物正式登陆中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fba614522579)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259948, encodeId=d00812599485c, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东申请扩大9价HPV疫苗用于27-45岁人群获FDA受理, objectType=article, longId=140874, objectId=5d321408e479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d321408e479, replyNumber=0, likeNumber=86, createdTime=2018-06-17, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d321408e479, moduleTitle=默沙东申请扩大9价HPV疫苗用于27-45岁人群获FDA受理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d321408e479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259947, encodeId=9e87125994e2b, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=祝贺！默沙东重磅丙肝新药择必达®在中国获批, objectType=article, longId=137653, objectId=71fa13e6531f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71fa13e6531f, replyNumber=0, likeNumber=67, createdTime=2018-05-11, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71fa13e6531f, moduleTitle=祝贺！默沙东重磅丙肝新药择必达®在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71fa13e6531f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259946, encodeId=00bb1259946ac, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=NICE批准默沙东的Keytruda用于治疗膀胱癌, objectType=article, longId=136973, objectId=10a31369e301, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10a31369e301, replyNumber=0, likeNumber=69, createdTime=2018-05-03, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10a31369e301, moduleTitle=NICE批准默沙东的Keytruda用于治疗膀胱癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10a31369e301)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259945, encodeId=4f68125994518, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=重磅！默沙东九价HPV疫苗有条件获批上市, objectType=article, longId=136865, objectId=6da1136865aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6da1136865aa, replyNumber=0, likeNumber=69, createdTime=2018-05-01, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6da1136865aa, moduleTitle=重磅！默沙东九价HPV疫苗有条件获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6da1136865aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259944, encodeId=06d9125994410, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=欧洲食品药品监督管理局启动默沙东的Keytruda/chemo联合用药的审查, objectType=article, longId=136410, objectId=261d13641072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=261d13641072, replyNumber=0, likeNumber=59, createdTime=2018-04-26, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=261d13641072, moduleTitle=欧洲食品药品监督管理局启动默沙东的Keytruda/chemo联合用药的审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=261d13641072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259943, encodeId=61e4125994353, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东Keytruda治疗胃癌获FDA加速批准, objectType=article, longId=114279, objectId=63a01142e962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63a01142e962, replyNumber=0, likeNumber=66, createdTime=2017-09-28, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63a01142e962, moduleTitle=默沙东Keytruda治疗胃癌获FDA加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63a01142e962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259942, encodeId=679b12599420e, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=3万人大型研究：默沙东新药首次降低心血管事件, objectType=article, longId=103679, objectId=19931036e9d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19931036e9d6, replyNumber=0, likeNumber=55, createdTime=2017-06-29, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19931036e9d6, moduleTitle=3万人大型研究：默沙东新药首次降低心血管事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19931036e9d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259941, encodeId=16c612599417e, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=默沙东支持血脂异常及动脉粥样硬化研究基金启动, objectType=article, longId=97002, objectId=9de99e0024e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9de99e0024e, replyNumber=0, likeNumber=75, createdTime=2017-04-27, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9de99e0024e, moduleTitle=默沙东支持血脂异常及动脉粥样硬化研究基金启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9de99e0024e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259940, encodeId=d8a0125994047, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下, objectType=article, longId=93675, objectId=64f6936e500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64f6936e500, replyNumber=0, likeNumber=63, createdTime=2017-03-29, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64f6936e500, moduleTitle=PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64f6936e500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259939, encodeId=0d2d1259939d0, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=步礼来后尘？默沙东抗痴呆药物临床失败！, objectType=article, longId=89073, objectId=81d2890e3b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81d2890e3b7, replyNumber=0, likeNumber=52, createdTime=2017-02-18, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81d2890e3b7, moduleTitle=步礼来后尘？默沙东抗痴呆药物临床失败！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81d2890e3b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259938, encodeId=7c481259938fe, content=<a href='/topic/show?id=6ff910336054' target=_blank style='color:#2F92EE;'>#默沙东#</a>, objectTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, objectType=article, longId=88246, objectId=abae8824611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abae8824611, replyNumber=0, likeNumber=75, createdTime=2017-02-05, rootId=0, userName=yese, userId=28d456, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abae8824611, moduleTitle=喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abae8824611)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

默沙东

2020-05-29

yese (审核中...)

前往app查看评论内容

#默沙东#

阿斯利康/默沙东的PARP抑制剂Lynparza获得欧盟批准，治疗转移性乳腺癌

2019-04-12

yese (审核中...)

前往app查看评论内容

#默沙东#

欧盟批准默沙东Keytruda的新剂量计划：每3周200mg改为每6周400mg

2019-04-07

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东3亿收购IMDZ

2019-02-24

仁医06 (审核中...)

前往app查看评论内容

#默沙东#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2019-02-20

yese (审核中...)

前往app查看评论内容

#默沙东#

卫材中国和默沙东中国共同举办仑伐替尼中国上市会

2019-01-18

yese (审核中...)

前往app查看评论内容

#默沙东#

罗氏、吉利德、默沙东……跨国公司高管大变动

2018-12-14

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东达成6.95亿美元合作，豪赌NK细胞疗法

2018-10-08

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东HIV新药Delstrigo和Pifeltro获得FDA批准上市

2018-09-02

yese (审核中...)

前往app查看评论内容

#默沙东#

重磅！默沙东Keytruda获批，第2个PD-1药物正式登陆中国

2018-07-28

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东申请扩大9价HPV疫苗用于27-45岁人群获FDA受理

2018-06-17

yese (审核中...)

前往app查看评论内容

#默沙东#

祝贺！默沙东重磅丙肝新药择必达®在中国获批

2018-05-11

yese (审核中...)

前往app查看评论内容

#默沙东#

NICE批准默沙东的Keytruda用于治疗膀胱癌

2018-05-03

yese (审核中...)

前往app查看评论内容

#默沙东#

重磅！默沙东九价HPV疫苗有条件获批上市

2018-05-01

yese (审核中...)

前往app查看评论内容

#默沙东#

欧洲食品药品监督管理局启动默沙东的Keytruda/chemo联合用药的审查

2018-04-26

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东Keytruda治疗胃癌获FDA加速批准

2017-09-28

yese (审核中...)

前往app查看评论内容

#默沙东#

3万人大型研究：默沙东新药首次降低心血管事件

2017-06-29

yese (审核中...)

前往app查看评论内容

#默沙东#

默沙东支持血脂异常及动脉粥样硬化研究基金启动

2017-04-27

yese (审核中...)

前往app查看评论内容

#默沙东#

PD-1/PD-L1抗体“钱途”诱人，BMS、默沙东、罗氏、辉瑞四分天下

2017-03-29

yese (审核中...)

前往app查看评论内容

#默沙东#

步礼来后尘？默沙东抗痴呆药物临床失败！

2017-02-18

yese (审核中...)

前往app查看评论内容

#默沙东#

喜讯！欧盟批准默沙东PD-1免疫疗法Keytruda一线治疗PD-L1阳性非小细胞肺癌（NSCLC）

2017-02-05

科室
- - 订阅+
  - 更多科室
工具
服务